Wolverine Trading’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-14,300
| Closed | -$134K | – | 5631 |
|
|
2025
Q2 | $134K | Sell |
14,300
-7,000
| -33% | -$65.2K | ﹤0.01% | 4086 |
|
|
2025
Q1 | $167K | Buy |
21,300
+2,600
| +14% | +$21K | ﹤0.01% | 4037 |
|
|
2024
Q4 | $141K | Sell |
18,700
-11,400
| -38% | -$86.5K | ﹤0.01% | 4684 |
|
|
2024
Q3 | $229K | Buy |
30,100
+100
| +0.3% | +$760 | ﹤0.01% | 3927 |
|
|
2024
Q2 | $185K | Buy |
30,000
+18,900
| +170% | +$104K | ﹤0.01% | 3875 |
|
|
2024
Q1 | $56.4K | Sell |
11,100
-10,800
| -49% | -$60.7K | ﹤0.01% | 4194 |
|
|
2023
Q4 | $131K | Buy |
21,900
+9,900
| +83% | +$57.4K | ﹤0.01% | 4029 |
|
|
2023
Q3 | $85K | Sell |
12,000
-4,000
| -25% | -$28.7K | ﹤0.01% | 4045 |
|
|
2023
Q2 | $111K | Sell |
16,000
-9,100
| -36% | -$73K | ﹤0.01% | 3739 |
|
|
2023
Q1 | $211K | Buy |
+25,100
| New | +$242K | ﹤0.01% | 3354 |
|
|
2022
Q4 | – | Sell |
-56,200
| Closed | -$695K | – | 3982 |
|
|
2022
Q3 | $695K | Buy |
56,200
+1,100
| +2% | +$14.2K | ﹤0.01% | 2298 |
|
|
2022
Q2 | $596K | Sell |
55,100
-19,500
| -26% | -$201K | ﹤0.01% | 2375 |
|
|
2022
Q1 | $1.23M | Buy |
+74,600
| New | +$1.2M | ﹤0.01% | 2233 |
|
|
2021
Q4 | – | Sell |
-96,600
| Closed | -$1.39M | – | 5836 |
|
|
2021
Q3 | $1.39M | Sell |
96,600
-22,500
| -19% | -$355K | ﹤0.01% | 2573 |
|
|
2021
Q2 | $1.84M | Buy |
119,100
+53,000
| +80% | +$720K | ﹤0.01% | 2073 |
|
|
2021
Q1 | $660K | Buy |
66,100
+7,000
| +12% | +$72.2K | ﹤0.01% | 3317 |
|
|
2020
Q4 | $443K | Buy |
59,100
+11,600
| +24% | +$59.8K | ﹤0.01% | 3304 |
|
|
2020
Q3 | $182K | Buy |
47,500
+15,900
| +50% | +$68.1K | ﹤0.01% | 3909 |
|
|
2020
Q2 | $157K | Buy |
31,600
+1,300
| +4% | +$5.19K | ﹤0.01% | 3957 |
|
|
2020
Q1 | $60K | Sell |
30,300
-2,800
| -8% | -$7.71K | ﹤0.01% | 4198 |
|
|
2019
Q4 | $107K | Buy |
+33,100
| New | +$83.3K | ﹤0.01% | 4261 |
|
|
2019
Q3 | – | Sell |
-76,300
| Closed | -$289K | – | 4314 |
|
|
2019
Q2 | $289K | Buy |
+76,300
| New | +$459K | ﹤0.01% | 3304 |
|
|
2019
Q1 | – | Sell |
-23,600
| Closed | -$186K | – | 4524 |
|
|
2018
Q4 | $186K | Buy |
23,600
+5,400
| +30% | +$42K | ﹤0.01% | 3736 |
|
|
2018
Q3 | $139K | Buy |
+18,200
| New | +$122K | ﹤0.01% | 4418 |
|
|
2017
Q4 | – | Sell |
-64,500
| Closed | -$338K | – | 4897 |
|
|
2017
Q3 | $338K | Buy |
+64,500
| New | +$330K | ﹤0.01% | 3104 |
|
|
2017
Q2 | – | Sell |
-52,800
| Closed | -$439K | – | 4265 |
|
|
2017
Q1 | $439K | Buy |
52,800
+6,000
| +13% | +$41.7K | ﹤0.01% | 2549 |
|
|
2016
Q4 | $296K | Sell |
46,800
-80,300
| -63% | -$418K | ﹤0.01% | 3280 |
|
|
2016
Q3 | $566K | Buy |
+127,100
| New | +$508K | ﹤0.01% | 2443 |
|
Other funds holding BCRX
DM
KCM
Wolverine Trading's BCRX Position: Q3 2024 in Review
Wolverine Trading sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 10,609 shares — an estimated $80.6K sold.
Wolverine Trading first reported a position in BCRX in Q3 2016 and held it in 19 quarters. The position peaked at $1.03M in Q2 2021. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.
- Wolverine Trading reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
- Wolverine Trading sold 10,609 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $80.6K.
- Wolverine Trading first reported a position in BioCryst Pharmaceuticals in Q3 2016 and held it in 19 quarters.
- Wolverine Trading's BioCryst Pharmaceuticals position peaked at $1.03M in Q2 2021.
- 257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.
Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.